Before starting pharmacotherapy, healthcare professionals should assess for secondary causes of obesity and exclude active eating disorders
Who is, and is not, a candidate The archetypal candidate is an adult, often in their forties through sixties, who is already training and eating well and wants to optimize body composition, recovery, sleep, or connective-tissue resilience
Our team has worked with research-grade peptides for years
This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimers disease, liver disease, PCOS, and more
So youre speculating that microdoses produce just enough visceral fat loss, perhaps undetectable on a scale, to explain benefits
Provider credentialing and payer enrollment services are available at $99 per payer, covering 900-plus payer networks with a 99% first-time approval rate